{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T23:59:11Z","timestamp":1790467151994,"version":"4.1.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,11,1]],"date-time":"2022-11-01T00:00:00Z","timestamp":1667260800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"vor","delay-in-days":365,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Transplantation and Cellular Therapy"],"published-print":{"date-parts":[[2022,11]]},"DOI":"10.1016\/j.jtct.2022.08.008","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T23:01:15Z","timestamp":1660345275000},"page":"767.e1-767.e11","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":18,"title":["Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis"],"prefix":"10.1016","volume":"28","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7394-5185","authenticated-orcid":false,"given":"Mohamed A.","family":"Kharfan-Dabaja","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2029-6753","authenticated-orcid":false,"given":"Tea","family":"Reljic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3067-4271","authenticated-orcid":false,"given":"Farah","family":"Yassine","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Taiga","family":"Nishihori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3326-2141","authenticated-orcid":false,"given":"Arni","family":"Kumar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitchell M.","family":"Tawk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9427-0711","authenticated-orcid":false,"given":"Katelyn","family":"Keller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ernesto","family":"Ayala","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bipin","family":"Savani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohamad","family":"Mohty","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3942-7370","authenticated-orcid":false,"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wael","family":"Saber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jtct.2022.08.008_bib0001","unstructured":"D'Souza A, Fretham C. Current uses and outcomes of hematopoietic cell transplantation (HCT): CIBMTR Summary Slides, 2018. Available at https:\/\/www.cibmtr.org. Accessed March 1, 2022."},{"key":"10.1016\/j.jtct.2022.08.008_bib0002","doi-asserted-by":"crossref","DOI":"10.1038\/s41409-019-0465-9","article-title":"The EBMT activity survey report 2017: a focus on allogeneic HCT for nonmalignant indications and on the use of non-HCT cell therapies","author":"Passweg","year":"2019","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0003","doi-asserted-by":"crossref","first-page":"1154","DOI":"10.1200\/JCO.2016.70.7091","article-title":"Myeloablative versus reduced-intensity hematopoietic cell transplantation for acute myeloid leukemia and myelodysplastic syndromes","volume":"35","author":"Scott","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0004","doi-asserted-by":"crossref","first-page":"1170","DOI":"10.1038\/bmt.2014.133","article-title":"Comparing i.v. BU dose intensity between two regimens (FB2 vs FB4) for allogeneic HCT for AML in CR1: a report from the Acute Leukemia Working Party of EBMT","volume":"49","author":"Kharfan-Dabaja","year":"2014","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0005","doi-asserted-by":"crossref","first-page":"1190","DOI":"10.1200\/JCO.2010.31.8121","article-title":"Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia","volume":"29","author":"Walter","year":"2011","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0006","doi-asserted-by":"crossref","first-page":"1228","DOI":"10.3109\/10428194.2012.741230","article-title":"Outcome of relapse after allogeneic stem cell transplant in patients with acute myeloid leukemia","volume":"54","author":"Devillier","year":"2013","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.08.008_bib0007","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1038\/sj.bmt.1705852","article-title":"Outcomes of patients with AML and MDS who relapse or progress after reduced intensity allogeneic hematopoietic cell transplantation","volume":"40","author":"Pollyea","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0008","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1001\/jamaoncol.2018.2091","article-title":"Association of second allogeneic hematopoietic cell transplant vs donor lymphocyte infusion with overall survival in patients with acute myeloid leukemia relapse","volume":"4","author":"Kharfan-Dabaja","year":"2018","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0009","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.bmt.1705011","article-title":"Disease burden may identify patients more likely to benefit from second allogeneic hematopoietic stem cell transplantation to treat relapsed acute myelogenous leukemia","volume":"36","author":"Hosing","year":"2005","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0010","unstructured":"Wells G, Shea B, O'Connell D, et al. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses2019."},{"key":"10.1016\/j.jtct.2022.08.008_bib0011","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/0197-2456(86)90046-2","article-title":"Meta-analysis in clinical trials","volume":"7","author":"DerSimonian","year":"1986","journal-title":"Control Clin Trials"},{"key":"10.1016\/j.jtct.2022.08.008_bib0012","series-title":"Kendall's advanced theory of statistics","author":"Kendall","year":"1987"},{"key":"10.1016\/j.jtct.2022.08.008_bib0013","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring inconsistency in meta-analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"key":"10.1016\/j.jtct.2022.08.008_bib0014","series-title":"StataCorp. Stata Statistical Software: Release 16","year":"2016"},{"key":"10.1016\/j.jtct.2022.08.008_bib0015","first-page":"39","article-title":"Metaprop: a Stata command to perform meta-analysis of binomial data","volume":"72","author":"Nyaga","year":"2014"},{"key":"10.1016\/j.jtct.2022.08.008_bib0016","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1000097","article-title":"Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement","volume":"6","author":"Moher","year":"2009","journal-title":"PLoS Med"},{"key":"10.1016\/j.jtct.2022.08.008_bib0017","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1200\/JCO.1993.11.2.304","article-title":"Second allogeneic marrow transplantation for patients with recurrent leukemia after initial transplant with total-body irradiation-containing regimens","volume":"11","author":"Radich","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0018","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1038\/sj.leu.2400585","article-title":"Second allogeneic bone marrow transplantation in acute leukemia: a multicenter study from the Gruppo Italiano Trapianto Di Midollo Osseo (GITMO)","volume":"11","author":"Bosi","year":"1997","journal-title":"Leukemia"},{"key":"10.1016\/j.jtct.2022.08.008_bib0019","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1046\/j.1365-2141.2000.01851.x","article-title":"Second allogeneic haematopoietic stem cell transplantation in relapsed acute and chronic leukaemias for patients who underwent a first allogeneic bone marrow transplantation: a survey of the Societe Francaise de Greffe de moelle (SFGM)","volume":"108","author":"Michallet","year":"2000","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0020","doi-asserted-by":"crossref","first-page":"3675","DOI":"10.1200\/JCO.2001.19.16.3675","article-title":"Second allogeneic bone marrow transplantation in acute leukemia: results of a survey by the European Cooperative Group for Blood and Marrow Transplantation","volume":"19","author":"Bosi","year":"2001","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0021","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.bmt.1704645","article-title":"Second transplant for acute and chronic leukemia relapsing after first HLA-identical sibling transplant","volume":"34","author":"Eapen","year":"2004","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0022","doi-asserted-by":"crossref","first-page":"783","DOI":"10.1038\/bmt.2008.255","article-title":"Outcome of second allogeneic transplants using reduced-intensity conditioning following relapse of haematological malignancy after an initial allogeneic transplant","volume":"42","author":"Shaw","year":"2008","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0023","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1002\/ajh.23439","article-title":"Primary treatment of leukemia relapses after allogeneic hematopoietic stem cell transplantation with reduced-intensity conditioning second transplantation from the original donor","volume":"88","author":"Leung","year":"2013","journal-title":"Am J Hematol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0024","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1038\/bmt.2015.186","article-title":"Second allogeneic transplantation for relapse of malignant disease: retrospective analysis of outcome and predictive factors by the EBMT","volume":"50","author":"Ruutu","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0025","doi-asserted-by":"crossref","first-page":"103","DOI":"10.3109\/10428194.2015.1045900","article-title":"Second allogeneic transplantation using unrelated cord blood for relapsed hematological malignancies after allogeneic transplantation","volume":"57","author":"Konuma","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.08.008_bib0026","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1016\/j.bbmt.2015.11.012","article-title":"Outcome of second allogeneic hematopoietic cell transplantation after relapse of myeloid malignancies following allogeneic hematopoietic cell transplantation: a retrospective cohort on behalf of the Grupo Espanol de Trasplante Hematopoyetico","volume":"22","author":"Orti","year":"2016","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0027","doi-asserted-by":"crossref","first-page":"1758","DOI":"10.1080\/10428194.2018.1542149","article-title":"Second allogeneic hematopoietic cell transplantation for relapse after first allografts","volume":"60","author":"Gyurkocza","year":"2019","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.08.008_bib0028","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/bmt.2012.267","article-title":"Reduced-intensity conditioning with fludarabine and thiotepa for second allogeneic transplantation of relapsed patients with AML","volume":"48","author":"Christopoulos","year":"2013","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0029","doi-asserted-by":"crossref","first-page":"1508","DOI":"10.1038\/bmt.2015.193","article-title":"Long-term outcome and prognostic factors of second allogeneic hematopoietic stem cell transplant for acute leukemia in patients with a median follow-up of 10 years","volume":"50","author":"Andreola","year":"2015","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0030","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1038\/bmt.2015.221","article-title":"Second reduced intensity conditioning allogeneic transplant as a rescue strategy for acute leukaemia patients who relapse after an initial RIC allogeneic transplantation: analysis of risk factors and treatment outcomes","volume":"51","author":"Vrhovac","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"10.1016\/j.jtct.2022.08.008_bib0031","doi-asserted-by":"crossref","first-page":"1403","DOI":"10.1080\/10428194.2016.1243678","article-title":"Outcome and prognostic factors among patients who underwent a second transplantation for disease relapse post the first allogeneic cell transplantation","volume":"58","author":"Tachibana","year":"2017","journal-title":"Leuk Lymphoma"},{"key":"10.1016\/j.jtct.2022.08.008_bib0032","doi-asserted-by":"crossref","first-page":"2491","DOI":"10.1007\/s00277-018-3454-y","article-title":"Second allogeneic hematopoietic cell transplantation enables long-term disease-free survival in relapsed acute leukemia","volume":"97","author":"Schneidawind","year":"2018","journal-title":"Ann Hematol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0033","doi-asserted-by":"crossref","first-page":"592","DOI":"10.1111\/bjh.17426","article-title":"Second allogeneic haematopoietic cell transplantation using HLA-matched unrelated versus T-cell replete haploidentical donor and survival in relapsed acute myeloid leukaemia","volume":"193","author":"Kharfan-Dabaja","year":"2021","journal-title":"Br J Haematol"},{"key":"10.1016\/j.jtct.2022.08.008_bib0034","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1016\/j.jtct.2021.05.007","article-title":"Outcomes of second allogeneic hematopoietic cell transplantation for patients with acute myeloid leukemia","volume":"27","author":"Yalniz","year":"2021","journal-title":"Transplant Cell Ther"}],"container-title":["Transplantation and Cellular Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015470?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666636722015470?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T03:07:08Z","timestamp":1763003228000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666636722015470"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11]]},"references-count":34,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2022,11]]}},"alternative-id":["S2666636722015470"],"URL":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.008","relation":{},"ISSN":["2666-6367"],"issn-type":[{"value":"2666-6367","type":"print"}],"subject":[],"published":{"date-parts":[[2022,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Efficacy of a Second Allogeneic Hematopoietic Cell Transplant in Relapsed Acute Myeloid Leukemia: Results of a Systematic Review and Meta-Analysis","name":"articletitle","label":"Article Title"},{"value":"Transplantation and Cellular Therapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtct.2022.08.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The American Society for Transplantation and Cellular Therapy. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}